Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab‑associated anaphylaxis

Pol Arch Intern Med. 2018 Aug 31;128(7-8):494-495. doi: 10.20452/pamw.4327. Epub 2018 Aug 31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anaphylaxis / chemically induced*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Rituximab / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Rituximab
  • obinutuzumab